---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-047168"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-10-15T13:30:14+00:00"
generated_at: "2026-10-15T13:31:20.017434+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# bioAffinity to sponsor CHEST 2026 Learning Theater on CyPath Lung and asthma/COPD research

## Summary
- bioAffinity Technologies (Nasdaq: BIAF, BIAFW) will sponsor a Learning Theater at CHEST 2026 on Oct. 21, 2026, 12:30-1:15 p.m. MST in Phoenix.
- Chief Medical Officer Gordon H. Downie, MD, PhD, will present on CyPath Lung for lung cancer risk stratification and pulmonary nodule management.
- CyPath Lung clinical trial data: 92% sensitivity, 87% specificity, 88% accuracy, 99% negative predictive value for small indeterminate nodules under 20 mm.
- Presentation will discuss preliminary data from an investigational asthma/COPD lung inflammation test.
- Medical and Scientific Advisory Board to meet; members include David Hill, David Ost, Daniel Sterman, Sheila Habib, J. Scott Ferguson, Neil Alexis and Sandeep Bansal.

## SEC filing metadata
- accession: 0001493152-26-047168
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-10-15T13:30:14+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226047168/0001493152-26-047168-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226047168/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-047168
- JSON: https://secwatch.observer/filing/0001493152-26-047168.json
- Plain text: https://secwatch.observer/filing/0001493152-26-047168.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.